ABSTRACT
Se realizó un estudio de picaduras de aracnomrofos en la ciudad de Sucre (Chuquisaca). El método comprendió el uso de encuestas semiestructuradas, donde se consultó sobre la percepción que tienen, sintomatologías y conocimiento local sobre métodos de curación. Los resultados obtenidos evidencian que la mayoría tiene fobia hacia los arácnidos. El conocimiento local, permite conocer los diferentes tipos de arañas y escorpiones que residen en los domicilios. Se describe los síntomas que causan debido al efecto de las picadas, además de los métodos convencionales y naturales de curación.
We study of pitting Arachnomorph´s was held in the city of Sucre (Chuquisaca). The method realized using semistructured interviews, which were consulted on the perception, symptom and local knowledge of healing methods. The results show that most have phobia of arachnids. Local knowledge, allows to know the different types of spiders and scorpions that live in the homes. They are causing symptoms due to the effect of bites and of natural and using the conventional and natural healing methods.
Subject(s)
Humans , Male , Female , Adolescent , Middle Aged , Aged , Aged, 80 and over , Phobic Disorders , Bites and Stings , Surveys and Questionnaires , MethodsABSTRACT
In the last few decades, the field of nanomedicine applied to cancer has revolutionized cancer treatment: several nanoformulations have already reached the market and are routinely being used in the clinical practice. In the case of genetic nanomedicines, i.e., designed to deliver gene therapies to cancer cells for therapeutic purposes, advances have been less impressive. This is because of the many barriers that limit the access of the therapeutic nucleic acids to their target site, and the lack of models that would allow for an improvement in the understanding of how nanocarriers can be tailored to overcome them. Zebrafish has important advantages as a model species for the study of anticancer therapies, and have a lot to offer regarding the rational development of efficient delivery of genetic nanomedicines, and hence increasing the chances of their successful translation. This review aims to provide an overview of the recent advances in the development of genetic anticancer nanomedicines, and of the zebrafish models that stand as promising tools to shed light on their mechanisms of action and overall potential in oncology.
ABSTRACT
Urea Cycle Disorders ( UCD ) are among the most common genetic diseases of the metabolism and ornithine transcarbamylase deficiency (OTC), an X-linked defect is the most frequent among them. It is responsible for hyperammonemia that can lead to chronic neurological illness and potentially to death in case of delayed diagnosis and treatment. With regards to the OTC deficiency there is great clinical heterogeneity with early-onset phenotypes with mostly poor prognosis and late-onset phenotypes with a better one. In the article it is reported the case of a 8 years old patient with diagnosis of OTC deficit with late-onset phenotype. The kid was brought to our hospital because of continuous vomiting and gastro- intestinal disorders, associated with irritability and lethargy later resulted into coma. Measurement of plasma ammonia concentration, followed by measurement of plasma amino acid and urine orotic acid levels allowed to diagnose the OTC deficit, lately confirmed by molecular genetic studies. The patient has been promptly treated with Sodium Phenylbutyrate, Arginine and discontinuing the protein intake. Gradually the ammonemia value decreased, and general and neurological conditions improved with resolution of the coma. To conclude, for patients presenting unexplained neurological symptoms, confusion and decreased level of consciousness, up to coma, urea cycle disorders and in particularly OTC deficiency should be considered in the differential diagnosis and an urgent ammonia level determined. In case of hyperammonemia, the treatment should be started immediately , even without a precise ethiologic diagnosis.
Subject(s)
Coma/etiology , Hyperammonemia/complications , Ornithine Carbamoyltransferase Deficiency Disease/complications , Arginine/administration & dosage , Child , Diagnosis, Differential , Fluid Therapy/methods , Humans , Hyperammonemia/diagnosis , Hyperammonemia/therapy , Lethargy/etiology , Male , Ornithine Carbamoyltransferase Deficiency Disease/diagnosis , Ornithine Carbamoyltransferase Deficiency Disease/genetics , Ornithine Carbamoyltransferase Deficiency Disease/therapy , Phenotype , Rehydration Solutions/administration & dosage , Treatment Outcome , Vomiting/etiologyABSTRACT
BACKGROUND: Samarium153 EDTMP, a beta and gamma emitter, is used in the palliative therapy of painful bone metastases. AIM: To evaluate the analgesic effects and myelotoxicity of Samarium153 EDTMP in patients with prostate, breast and renal carcinoma. PATIENTS AND METHODS: Twenty patients with bone metastases (11 males), aged 65 years old as a mean, received a 1 to 2 mCi/kg intravenous dose of Samarium153 EDTMP, produced in Chile. Patients were followed thereafter during 4 to 40 weeks. Pain was assessed using a visual analogue scale. RESULTS: Pain decreased from a score of 6.4 prior to treatment, to 2.7 at the fourth week of therapy and the effect lasted a mean of 12.5 weeks. Myelotoxicity was observed in 68% of cases (WHO stage I in 21%, stage II in 37%, stage III in 11% and no patients in stage IV). Platelets were the most affected series and neutrophils the least affected. Cell counts returned to normal between the sixth and eighth week. Seventy nine percent of patients decreased their basal analgesic therapy at the sixth week and 88% did so at the eighth week. Forty one percent of these patients discontinued all analgesics. CONCLUSIONS: Samarium153 EDTMP is effective in the treatment of pain in patients with bone metastases and its myelotoxicity is low to moderate. It should be considered as a therapy for this type of pain, with the precaution of performing periodical bood counts.
